These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25060671)

  • 21. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.
    Darpo B
    Br J Pharmacol; 2010 Jan; 159(1):49-57. PubMed ID: 19922536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute.
    Vargas HM; Rossman EI; Wisialowski TA; Nichols J; Pugsley MK; Roche B; Gintant GA; Greiter-Wilke A; Kleiman RB; Valentin JP; Leishman DJ
    J Pharmacol Toxicol Methods; 2023; 121():107265. PubMed ID: 36997076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. QT as a safety biomarker in drug development.
    Whellan DJ; Green CL; Piccini JP; Krucoff MW
    Clin Pharmacol Ther; 2009 Jul; 86(1):101-4. PubMed ID: 19474784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular predictors of drug-induced prolongation of the QT interval.
    Dilaveris PE
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Apr; 3(2):105-18. PubMed ID: 15853698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant.
    Murphy PJ; Yasuda S; Nakai K; Yoshinaga T; Hall N; Zhou M; Aluri J; Rege B; Moline M; Ferry J; Darpo B
    J Clin Pharmacol; 2017 Jan; 57(1):96-104. PubMed ID: 27338807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of six commonly used QT correction models and their parameter estimation methods.
    Wang D; Taubel J; Arezina R
    J Biopharm Stat; 2012; 22(6):1148-61. PubMed ID: 23075014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary.
    Darpo B; Ferber G
    J Clin Pharmacol; 2021 Oct; 61(10):1261-1273. PubMed ID: 33896027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.
    Shah RR; Morganroth J
    Drug Saf; 2012 Sep; 35(9):695-709. PubMed ID: 22845313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Bias Evaluation Provide Protection Against False-Negative Results in QT Studies Without a Positive Control Using Exposure-Response Analysis?
    Ferber G; Zhou M; Dota C; Garnett C; Keirns J; Malik M; Stockbridge N; Darpo B
    J Clin Pharmacol; 2017 Jan; 57(1):85-95. PubMed ID: 27271102
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of baseline measurement on the change from baseline in QTc intervals.
    Tian H; Natarajan J
    J Biopharm Stat; 2008; 18(3):542-52. PubMed ID: 18470762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Model-based evaluation of drug-induced QTc prolongation for compounds in early development.
    Dubois VF; Yu H; Danhof M; Della Pasqua O;
    Br J Clin Pharmacol; 2015 Jan; 79(1):148-61. PubMed ID: 25099645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The thorough QT study - do we need more of the same?
    Loke YK
    Br J Clin Pharmacol; 2016 Mar; 81(3):400-1. PubMed ID: 26692294
    [No Abstract]   [Full Text] [Related]  

  • 35. Assessing electrocardiographic data quality and possible replacement of pharmacologic positive control in thorough QT/QTc studies by investigations of drug-free QTc stability.
    Malik M; Zhang J; Johannesen L; Hnatkova K; Garnett C
    Heart Rhythm; 2011 Nov; 8(11):1777-85. PubMed ID: 21699874
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity.
    Shah RR
    Fundam Clin Pharmacol; 2002 Apr; 16(2):147-56. PubMed ID: 12031067
    [No Abstract]   [Full Text] [Related]  

  • 37. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
    Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
    J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. April 11-12, 2005, Bethesda, MD, USA.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2005 Jul; 4(4):795-9. PubMed ID: 16011455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
    Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
    Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
    Stylianou A; Roger J; Stephens K
    J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.